Beranda › Kanker Payudara › California › Mountain View
Uji klinis Kanker Payudara di Mountain View, CA
26 studi untuk Kanker Payudara mencari peserta di lokasi sekitar Mountain View (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Menerima pesertaFase 3
- Stanford Women's Cancer Center, Palo Alto · 5 mi jauhnya
A Study of PHST001 in Advanced Solid Tumors
Menerima pesertaFase 1
- Stanford University School of Medicine, Palo Alto · 5 mi jauhnya
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Menerima pesertaFase 3
- El Camino Hospital, Mountain View
- Palo Alto Medical Foundation, Mountain View
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Menerima pesertaFase 1/2
- Stanford Medicine Cancer Center, Stanford · 5 mi jauhnya
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Menerima pesertaFase 3
- El Camino Hospital Cancer Center ( Site 0096), Mountain View
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Menerima pesertaFase 1
- Stanford University Medical Center, Stanford · 5 mi jauhnya
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Menerima pesertaFase 1
- Stanford University Medical Center, Stanford · 5 mi jauhnya
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Menerima pesertaFase 3
- Stanford Cancer Center, Palo Alto · 5 mi jauhnya
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Menerima pesertaFase 3
- Stanford University School of Medicine - Stanford Cancer Institute (SCI) - Stanford Women's Cancer Center, Palo Alto · 5 mi jauhnya
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Menerima pesertaFase 3
- Stanford Women's Cancer Center, Palo Alto · 5 mi jauhnya
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Menerima pesertaFase 1
- Stanford University Hospital, Stanford · 5 mi jauhnya
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Menerima pesertaFase 3
- Research Site, Palo Alto · 5 mi jauhnya
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Menerima pesertaFase 2
- Stanford Cancer Institute, Palo Alto · 5 mi jauhnya
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Menerima pesertaFase 3
- Palo Alto Medical Foundation Research Center, Palo Alto · 5 mi jauhnya
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Menerima pesertaFase 3
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · 5 mi jauhnya
- dan 1 lainnya
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
Menerima pesertaFase 2
- Stanford University, Stanford · 5 mi jauhnya
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Menerima pesertaFase 2/3
- Local Institution - 0358, Stanford · 5 mi jauhnya
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Menerima pesertaFase 3
- Stanford Medicine Cancer Center - Stanford Women's Cancer Center, Palo Alto · 5 mi jauhnya
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Menerima pesertaFase 1
- Stanford University Medical Center, Palo Alto · 5 mi jauhnya
Magnetic Resonance Imaging of Breast Cancer
Menerima pesertaSukarelawan sehat diterima
- Stanford University School of Medicine, Stanford · 5 mi jauhnya
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
Menerima pesertaStudi observasional
- Stanford University School of Medicine, Stanford · 5 mi jauhnya
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Menerima pesertaFase 3
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · 5 mi jauhnya
- Stanford Cancer Institute Palo Alto, Palo Alto · 5 mi jauhnya
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Menerima pesertaFase 1
- Stanford Cancer Institute, Stanford · 5 mi jauhnya
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
Menerima peserta
- Stanford University, Stanford · 5 mi jauhnya
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Menerima pesertaStudi observasional
- Stanford Cancer Institute, Palo Alto · 5 mi jauhnya
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Stanford · 5 mi jauhnya
Uji klinis Kanker Payudara di kota lain
- New York City, NY136 studi
- Houston, TX126 studi
- Boston, MA112 studi
- Nashville, TN81 studi
- Los Angeles, CA73 studi
- Edison, NJ68 studi
- St. Louis, MO64 studi
- Queens, NY64 studi
- Durham, NC64 studi
- Chicago, IL59 studi
- Philadelphia, PA56 studi
- Dallas, TX55 studi
Studi lain di Mountain View
- Kanker (semua jenis)40 studi
- Kanker Metastatik25 studi
- Kanker Paru Non-Sel Kecil21 studi
- Leukemia Mieloid Akut19 studi
- Kanker Ovarium19 studi
- Gangguan Spektrum Autisme17 studi
- Kanker Paru17 studi
- Kanker Prostat15 studi
- Gagal Jantung15 studi
- Autisme13 studi
- Leukemia Limfoblastik Akut13 studi
- Kanker Kolorektal13 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.